Novel Voxel-Based MRI Risk Score LADCT 2 as a Tool for Prediction of Prostate Cancer: A Proof of Concept With Retrospective Study
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Introduction Biparametric magnetic resonance imaging (MRI) preserves enough information to enable the prediction of prostate cancer (PCa). This fast, cost-effective, and non-invasive modality includes acquisition of T2-weighted images, and accelerated diffusion-weighted imaging (DWI) sequences with corresponding apparent diffusion coefficient (ADC) maps. In this proof-of-concept study, we aimed to assess the prediction of PCa using a tumor location-(L) dependent risk score (LADCT 2 ) generated from an ADC and T2 images - based model. Methods The single-center institutional retrospective cohort study used 113 patients who underwent multiparametric MRI (mpMRI) for the diagnosis and management of PCa. A discovery cohort (n = 58) and an evaluation cohort (n = 55) were identified from a prospectively maintained institutional cancer registry. The discovery cohort consisted of patients who underwent MRI-guided TRUS biopsies, whereas the evaluation cohort consisted of patients who received only standard TRUS biopsy. Among the discovery cohort, we developed a predictive risk score (LADCT 2 ) using a multivariable logistic regression model that incorporated tumor location (L) with normalized mean signal differences of T2-and ADC- tumor region of interest. The primary outcome assessed the predictive accuracy of the LADCT 2 risk score in predicting PCa. Results Our results demonstrated that the LADCT 2 score exhibited excellent predictive accuracy for PCa among both the evaluation (AUC = 0.84, OR = 2.80 [95% CI, 1.04-7.52]; P = .04), and discovery (AUC = 0.77, OR = 2.71 [95% CI, 1.38-5.35]; P = .003) cohorts. Additionally, it also predicted for clinically significant PCa among both the discovery (AUC = 0.71, OR = 2.11 [95% CI, 1.16-3.84]; P = .01), and evaluation (AUC = 0.65, OR = 1.94 [95% CI, 1.02-3.69]; P = .04) cohorts. Conclusion The novel LADCT 2 risk score may function as an effective risk stratification tool to support clinical decision-making in the management of PCa.
Fields of Study & Subjects
Prostate Cancer Diagnosis and Treatment
MRI in cancer diagnosis
Radiomics and Machine Learning in Medical Imaging
Publication details
- Journal / source
- Cancer Control
- Volume
- 33
- Pages
- 10732748261433288–10732748261433288
- Publication date
- 1 March 2026
- Language
- EN